Novel approaches, including CDK4/6 and PI3K/mTOR inhibitors, offer combinatorial benefits in HR+/HER2– breast cancer, yet resistance mechanisms necessitate further exploration of alternative signaling cascades and immune-modulating strategies [13,14]. This evidence concerns the gene MTOR and breast cancer.